- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07919834
Ultrasonographic Tissue Thickness After Complex Decongestive Therapy in Lower-Limb Lymphedema
Effect of Complex Decongestive Therapy on Subcutaneous Tissue Thickness in Lower-Limb Lymphedema: A Prospective Ultrasonographic Study With Contralateral Internal Control
This prospective single-center study evaluated whether 4 weeks of phase-1 complex decongestive therapy (manual lymphatic drainage, multilayer short-stretch bandaging, decongestive exercise, and skin care) changes dermal and subcutaneous tissue thickness measured by high-frequency ultrasonography in adults with unilateral International Society of Lymphology stage 1-2 lower-limb lymphedema. Measurements were made at suprapatellar and infrapatellar sites of both limbs before and after treatment; the unaffected limb served as an internal control and body weight was recorded to distinguish local tissue change from systemic weight change.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Participants received a standardized 20-session (5 days/week, 4 weeks) intensive-phase complex decongestive therapy program delivered by an experienced physiotherapist. Ultrasonographic measurements were performed with a 10-14 MHz linear probe using a minimal-compression technique after 15 minutes of supine rest, at the same time of day, by an assessor blinded to baseline values; intra-rater reliability (intraclass correlation coefficient 0.92) was established in 10 patients. The sample size (n = 34; Cohen's d = 0.5, power 80%, alpha 0.05; 40 recruited) was calculated with G*Power. Paired comparisons (paired t-test or Wilcoxon signed-rank test), 95% confidence intervals, Cohen's d, and Pearson correlation of treatment response with age, body mass index, and disease duration were planned.
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
-
Kayseri, Turquie (Türkiye), 38080
- Kayseri City Training and Research Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Adults presenting to the Physical Medicine and Rehabilitation outpatient clinic of Kayseri City Hospital with unilateral lower-limb lymphedema and an indication for intensive-phase complex decongestive therapy.
La description
Inclusion Criteria:
- Age 18 years or older
- Unilateral lower-limb lymphedema, International Society of Lymphology stage 1 or 2 (2020 consensus)
- Diagnosis supported by lymphoscintigraphy
- Indication for intensive-phase complex decongestive therapy
- No previous full course of complex decongestive therapy on the affected limb
- Written informed consent
Exclusion Criteria:
- Active cellulitis or erysipelas at the measurement sites
- Active, recurrent, or metastatic malignancy
- Decompensated heart failure or history of deep vein thrombosis
- Bilateral lymphedema
- Cognitive impairment preventing adherence to treatment
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Lower-limb lymphedema, complex decongestive therapy
Adults with unilateral ISL stage 1-2 lower-limb lymphedema who received 4 weeks (20 sessions) of phase-1 complex decongestive therapy as standard care. Dermal and subcutaneous tissue thickness were measured by high-frequency ultrasonography at suprapatellar and infrapatellar sites of both limbs before and after treatment; the unaffected limb served as an internal control. |
Phase-1 (intensive) complex decongestive therapy delivered 5 days per week for 4 weeks (20 sessions) by an experienced physiotherapist: Vodder-technique manual lymphatic drainage (30-45 min), multilayer short-stretch compression bandaging from the toes to the proximal thigh, decongestive range-of-motion exercise performed with bandages in place, and daily skin care with a pH 5.5 moisturizer.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in subcutaneous tissue thickness of the affected limb at the suprapatellar site
Délai: Baseline and end of week 4 (after 20 sessions of complex decongestive therapy)
|
Subcutaneous tissue thickness (dermis-subcutis interface to deep fascia) measured in millimeters by B-mode ultrasonography with a 10-14 MHz linear probe using a minimal-compression technique. |
Baseline and end of week 4 (after 20 sessions of complex decongestive therapy)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in subcutaneous tissue thickness of the affected limb at the infrapatellar site
Délai: Baseline and end of week 4
|
Subcutaneous tissue thickness in millimeters measured by B-mode ultrasonography (10-14 MHz linear probe, minimal-compression technique). |
Baseline and end of week 4
|
|
Change in dermal thickness of the affected limb at the suprapatellar and infrapatellar sites
Délai: Baseline and end of week 4
|
Dermal thickness (skin surface to dermis-subcutis interface) in millimeters measured by B-mode ultrasonography. |
Baseline and end of week 4
|
|
Change in subcutaneous tissue thickness of the unaffected (control) limb
Délai: Baseline and end of week 4
|
Subcutaneous tissue thickness of the contralateral unaffected limb at the suprapatellar and infrapatellar sites, in millimeters, measured by B-mode ultrasonography; serves as an internal control. |
Baseline and end of week 4
|
|
Change in body weight
Délai: Baseline and end of week 4
|
Body weight in kilograms measured on the same calibrated scale, recorded to distinguish local tissue change from systemic weight change. |
Baseline and end of week 4
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Correlation of subcutaneous thickness change with disease duration, age, and body mass index
Délai: Baseline and end of week 4
|
Pearson correlation coefficients between the change in suprapatellar subcutaneous thickness of the affected limb and disease duration (months), age (years), and body mass index (kg/m2). |
Baseline and end of week 4
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Abdullah Goktug Yazar, MD, Kayseri City Hospital
- Chaise d'étude: Ayse Guc, MD, Kayseri City Hospital
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2025-491
- 491 (Autre identifiant: Kayseri City Hospital Clinical Research Ethics Committee)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .